Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 CAD | +1.28% | +4.41% | +464.29% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
Business Summary
Number of employees: 16
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 11-09-30 | |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
David Hyman
DFI | Director of Finance/CFO | - | Feb. 13 |
Delphine Davan
IRC | Investor Relations Contact | - | 23-08-13 |
Minh To
PRN | Corporate Officer/Principal | - | 23-08-13 |
Eamonn Peters
PRN | Corporate Officer/Principal | - | 23-08-13 |
Evelyn Pau
PRN | Corporate Officer/Principal | - | 23-08-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 19-09-23 |
Albert Beraldo
BRD | Director/Board Member | - | 16-11-21 |
Fahar Merchant
CEO | Chief Executive Officer | - | 15-02-01 |
Founder | - | 11-09-30 | |
Jack Geltosky
BRD | Director/Board Member | 78 | 20-09-29 |
John Sampson
BRD | Director/Board Member | - | 21-09-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 74,778,857 | 53,700,082 ( 71.81 %) | 0 | 71.81 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+459.52% | 128M | |
+67.22% | 62.86B | |
-1.30% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.45% | 26.46B | |
-21.93% | 18.9B | |
+4.10% | 12.67B | |
+24.01% | 12.27B | |
+29.12% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- Company Medicenna Therapeutics Corp.